Journals / The European Research Journal / 2020 / Cilt: 6 - Sayı: 5

Is ischemia modified albumin a good marker in acute exacerbation of chronic obstructive pulmonary disease?

Pages
388–394
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, no correlation weredetermined between the parameters of arterial blood gas and pulmonary function.Conclusions: Although IMA values showed significant increase during acute exacerbation of COPD anddecreased after treatment, CRP still appeared more effective in evaluating the exacerbation status and followingup of the treatment of patients with COPD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Our aim is to compare the Ischemia modified albumin (IMA) in patients with acute exacerbationof Chronic Obstructive Pulmonary Disease (COPD) with a high oxidative and inflammatory biologic markerlike C-reactive protein (CRP) and to investigate its employability in AECOPD and the relationship betweenarterial blood gas and pulmonary function parameters.Methods: Forty-six patients diagnosed with acute exacerbation of COPD between March 2015 - September2016 at Ufuk University School of Medicine were included.
📊
Key Findings & Data:The 1st and 5th days of IMA and CRP levels weremeasured.
💡
Conclusion & Impact:Also, no correlation weredetermined between the parameters of arterial blood gas and pulmonary function.Conclusions: Although IMA values showed significant increase during acute exacerbation of COPD anddecreased after treatment, CRP still appeared more effective in evaluating the exacerbation status and followingup of the treatment of patients with COPD.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Our aim is to compare the Ischemia modified albumin (IMA) in patients with acute exacerbationof Chronic Obstructive Pulmonary Disease (COPD) with a high oxidative and inflammatory biologic markerlike C-reactive protein (CRP) and to investigate its employability in AECOPD and the relationship betweenarterial blood gas and pulmonary function parameters.Methods: Forty-six patients diagnosed with acute exacerbation of COPD between March 2015 - September2016 at Ufuk University School of Medicine were included. The 1st and 5th days of IMA and CRP levels weremeasured. Also, IMA levels were given in absorbance units (ABSU).Results: Total 46 patients of COPD, 13 (28.3%) were females and 33 (71.76%) were males. The mean age ofthe patients was 71.39 ± 10.04 years. The 1st and 5th day values of IMA, ABSU and CRP were 1.08 ± 0.33and 0.49 ± 0.24; 1.06 ± 0.34 and 0.49 ± 0.26; and 29.25 (3.10-288.00) and 6.35 (0.30-149.00), respectively (p< 0.001). No significant correlation was determined between IMA and CRP. Also, no correlation weredetermined between the parameters of arterial blood gas and pulmonary function.Conclusions: Although IMA values showed significant increase during acute exacerbation of COPD anddecreased after treatment, CRP still appeared more effective in evaluating the exacerbation status and followingup of the treatment of patients with COPD.

🔖

Cite This Article

Ogan, N., Çandar, T., Gülhan, M., Alhan, A., Evri, T. (2022). Is ischemia modified albumin a good marker in acute exacerbation of chronic obstructive pulmonary disease?. The European Research Journal, Cilt: 6 - Sayı: 5, 388–394. https://ajindex.com/articles/597502

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Global Strategy for Prevention, Diagnosis and Management of COPD. Available at: https://goldcopd.org/goldreports/. Accessed February 21, 2019. 2. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011;6:413-21. 3. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-60. 4. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96. 5. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74. 6. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5. 7. Hazini A, Cemek M, Isıldak I, Alpdagtaş S, Onul A, Senel U, et al. Investigation of ischemia modified albumin, oxidant and antioxidant markers in acute myocardial infarction. Postep Kardiol Inter 2015;11:298-303. 8. Nepal M, Jaisawal S, Guragain M, Kafle P, Mukkera S, Kumar R, et al. Ischemic modified albumin (IMA) as a novel marker for ischemic heart disease and surrogate marker for other high oxidative-ischemic conditions. J Cardiovasc Dis Res 2017;8:112- 6. 9. Jena I, Nayak SR, Behera S, Singh B, Ray S, Jena D, et al. Evaluation of ischemia-modified albumin, oxidative stress, and antioxidant status in acute ischemic stroke patients J Nat Sci Biol Med 2017;8:110-3. 10. Guntas G, Sahin A, Duran S, Kahraman R, Duran I, Sonmez C, et al. Evaluation of Ischemia-Modified Albumin in Patients with Inflammatory Bowel Disease. Clin Lab 2017;63:341-7. 11. Kumar P, Subramanian K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease. J Clin Diagn Res 2016;10:9-12. 12. Ozben S, Huseyinoglu N, Hanikoglu F, Guvenc TS, Yildirim BZ, et al. Advanced oxidation protein products and ischaemiamodified albumin in obstructive sleep apnea. Eur J Clin Invest 2014;44:1045-52. 13. Turedi S, Gunduz A, Mentese A, Topbas M, Karahan SC, Yeniocak S, et al. The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res 2008;9:1-12. 14. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Ischemia-modified albumin predicts mor